Precision BioSciences Begins Clinical Trial for Duchenne Muscular Dystrophy Gene Therapy

Precision BioSciences has initiated patient screening and enrollment for its Phase 1/2 FUNCTION-DMD study. This trial evaluates PBGENE-DMD, an in vivo gene editing treatment for Duchenne muscular dystrophy, targeting specific genetic mutations. The study aims to assess the safety, tolerability, and efficacy of the therapy in ambulatory patients.